GER
MCID: GST092
MIFTS: 64

Gastroesophageal Reflux (GER)

Categories: Gastrointestinal diseases

Aliases & Classifications for Gastroesophageal Reflux

MalaCards integrated aliases for Gastroesophageal Reflux:

Name: Gastroesophageal Reflux 57 12 76 29 13 6 44
Gastroesophageal Reflux Disease 57 12 37 55 15 73
Gerd 57 12 43
Gerd - Gastro-Esophageal Reflux Disease 12
Gastroesophageal Reflux Disease; Gerd 57
Gastroesophageal Reflux, Pediatric 57
Gastro-Esophageal Reflux 12
Gastresophageal Reflux 12
Acid Reflux 12
Ger 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
gastroesophageal reflux:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 109350
Disease Ontology 12 DOID:8534
ICD10 33 K21 K21.9
ICD9CM 35 530.81
MeSH 44 D005764
MedGen 42 C0017168
KEGG 37 H01602
UMLS 73 C0017168

Summaries for Gastroesophageal Reflux

MedlinePlus : 43 Your esophagus is the tube that carries food from your mouth to your stomach. Gastroesophageal reflux disease (GERD) happens when a muscle at the end of your esophagus does not close properly. This allows stomach contents to leak back, or reflux, into the esophagus and irritate it. You may feel a burning in the chest or throat called heartburn. Sometimes, you can taste stomach fluid in the back of the mouth. If you have these symptoms more than twice a week, you may have GERD. You can also have GERD without having heartburn. Your symptoms could include a dry cough, asthma symptoms, or trouble swallowing. Anyone, including infants and children, can have GERD. If not treated, it can lead to more serious health problems. In some cases, you might need medicines or surgery. However, many people can improve their symptoms by Avoiding alcohol and spicy, fatty or acidic foods that trigger heartburn Eating smaller meals Not eating close to bedtime Losing weight if needed Wearing loose-fitting clothes NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Gastroesophageal Reflux, also known as gastroesophageal reflux disease, is related to peptic esophagitis and barrett esophagus, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Gastroesophageal Reflux is CHAT (Choline O-Acetyltransferase), and among its related pathways/superpathways are Peptide ligand-binding receptors and Folate Metabolism. The drugs Dexlansoprazole and Lansoprazole have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and kidney, and related phenotypes are gastroesophageal reflux and esophagitis

OMIM : 57 Gastroesophageal reflux (GER) is characterized by the retrograde movement of stomach contents into the esophagus. In its most severe form, GER results in extensive tissue damage caused by acid reflux. In adolescents and adults, and even infrequently in children, chronic GER is associated with the risk of developing Barrett metaplasia (614266), a premalignant lesion of the esophageal mucosa (Hu et al., 2000). In turn, Barrett metaplasia is correlated with the development of adenocarcinoma of the esophagus (see 614266), estimated as the fifth most prevalent neoplasia in the Western world (Lagergren et al., 1999). (109350)

Wikipedia : 76 Gastroesophageal reflux disease (GERD), also known as acid reflux, is a long-term condition where... more...

Related Diseases for Gastroesophageal Reflux

Diseases related to Gastroesophageal Reflux via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 244)
# Related Disease Score Top Affiliating Genes
1 peptic esophagitis 32.8 CXCL8 CYP2C19 HRH2 IL1B
2 barrett esophagus 32.5 CDX2 GAST PTGS2 TP53
3 gastroparesis 32.4 CCK GAST GHRL MLN
4 helicobacter pylori infection 30.9 CXCL8 CYP2C19 GAST IL1B TP53
5 irritable bowel syndrome 30.7 CCK MLN TRPV1
6 esophagitis 30.6 CCL26 CXCL8 CYP2C19 HRH2 IL1B PTGS2
7 pharyngitis 30.6 CXCL8 IL1B PTGS2
8 bile reflux 30.6 CCK CDX2 PTGS2
9 zollinger-ellison syndrome 30.5 GAST HRH2 NTS
10 pylorospasm 30.4 GAST GHRL MLN
11 duodenogastric reflux 30.1 CCK GAST MLN NTS PYY
12 duodenal ulcer 30.1 CCK CXCL8 CYP2C19 GAST HRH2 IL1B
13 bulimia nervosa 30.1 CCK GHRL PYY
14 morbid obesity 30.1 CCK GCG GHRL PYY
15 bronchial disease 29.9 CXCL8 IL1B TRPV1
16 dumping syndrome 29.8 GCG NTS PYY
17 dyspepsia 29.7 CCK CXCL8 CYP2C19 GHRL HRH2 PTGS1
18 atrophic gastritis 29.6 CDX2 CXCL8 GAST GHRL IL1B TP53
19 peptic ulcer disease 29.1 CXCL8 CYP2C19 GAST GHRL HRH2 IL1B
20 gastritis 29.0 CDX2 CXCL8 GAST GHRL HRH2 IL1B
21 gastric ulcer 28.7 CXCL8 CYP2C19 GAST HRH2 IL1B PTGS1
22 constipation 28.5 CCK CHAT GAST MLN NTS PYY
23 central nervous system disease 28.3 CHAT IL1B TRPV1
24 inflammatory bowel disease 27.2 CXCL8 IL1B PTGS1 PTGS2 TRPV1
25 gastrointestinal system disease 26.4 CCK CXCL8 GAST GCG GHRL IL1B
26 neuropathy, hereditary sensory and autonomic, type i, with cough and gastroesophageal reflux 12.5
27 spastic paraplegia 9a, autosomal dominant 11.5
28 spastic paraplegia 9 11.5
29 hernia, hiatus 11.4
30 chronic laryngitis 11.4
31 chronic hiccups 11.4
32 jackhammer esophagus 11.3
33 neuropathy, hereditary sensory and autonomic, type iia 11.2
34 sudden infant death with dysgenesis of the testes syndrome 11.2
35 mental retardation, autosomal dominant 47 11.2
36 down syndrome 11.0
37 dihydropyrimidinase deficiency 11.0
38 lubs x-linked mental retardation syndrome 11.0
39 encephalopathy, neonatal severe, due to mecp2 mutations 11.0
40 mental retardation, x-linked 98 11.0
41 phelan-mcdermid syndrome 11.0
42 combined oxidative phosphorylation deficiency 19 11.0
43 mitochondrial neurogastrointestinal encephalopathy disease 11.0
44 diffuse cutaneous systemic sclerosis 11.0
45 proximal spinal muscular atrophy 11.0
46 severe congenital nemaline myopathy 11.0
47 swallowing disorders 11.0
48 recurrent corneal erosion 10.7 CXCL8 IL1B
49 bagassosis 10.7 CXCL8 IL1B
50 postcholecystectomy syndrome 10.6 CCK GAST MLN

Comorbidity relations with Gastroesophageal Reflux via Phenotypic Disease Network (PDN): (show all 14)


Acute Cystitis Anxiety
Bronchitis Chronic Myocardial Ischemia
Deficiency Anemia Dyskinesia of Esophagus
Esophagitis Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Ischemic Heart Disease
Osteoporosis Peptic Esophagitis

Graphical network of the top 20 diseases related to Gastroesophageal Reflux:



Diseases related to Gastroesophageal Reflux

Symptoms & Phenotypes for Gastroesophageal Reflux

Symptoms via clinical synopsis from OMIM:

57
GI:
chronic ulcerating esophagitis
gastroesophageal reflux

Lab:
columnar epithelium-lined distal esophagus

Oncology:
adenocarcinoma of the esophagus risk about 10%


Clinical features from OMIM:

109350

Human phenotypes related to Gastroesophageal Reflux:

32
# Description HPO Frequency HPO Source Accession
1 gastroesophageal reflux 32 HP:0002020
2 esophagitis 32 HP:0100633
3 barrett esophagus 32 HP:0100580

UMLS symptoms related to Gastroesophageal Reflux:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Gastroesophageal Reflux:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.77 CCK CDX2 CHAT GAST GHRL HRH2
2 digestive/alimentary MP:0005381 9.76 GAST GHRL HRH2 PTGS1 PTGS2 TP53
3 adipose tissue MP:0005375 9.73 PYY TP53 TRPV1 GHRL NTS PTGS2
4 neoplasm MP:0002006 9.17 CDX2 GAST IL1B PTGS1 PTGS2 TP53

Drugs & Therapeutics for Gastroesophageal Reflux

Drugs for Gastroesophageal Reflux (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 567)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 138530-94-6, 103577-45-3 9578005
2
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 103577-45-3 3883
3
Alginic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-32-7
4
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 73590-58-6 4594
5
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
6
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 57808-66-9 3151
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
8
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
9
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 2,Not Applicable 90566-53-3 62924
10
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 117976-89-3 5029
11
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 102625-70-7 4679
12
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 723-46-6 5329
13
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 738-70-5 5578
14
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
15
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75614-87-8, 51-45-6 774
16
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1134-47-0 2284
17
Menthol Approved Phase 4,Phase 3,Not Applicable 2216-51-5 16666
18
Magnesium hydroxide Approved, Investigational Phase 4,Phase 1,Not Applicable 1309-42-8
19
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
20
Pectin Approved, Investigational, Vet_approved Phase 4 9000-69-5 441476
21
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3 67-20-9 5353830
22
Nortriptyline Approved Phase 4,Phase 3,Phase 2 72-69-5 4543
23
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 21645-51-2
24 Magnesium trisilicate Approved Phase 4,Phase 3,Phase 1,Not Applicable 14987-04-3
25
Cimetidine Approved, Investigational Phase 4 51481-61-9 2756
26
Famotidine Approved Phase 4,Phase 2,Phase 3,Not Applicable 76824-35-6 3325
27
Metoclopramide Approved, Investigational Phase 4,Phase 3,Not Applicable 364-62-5 4168
28
Nizatidine Approved Phase 4,Phase 3 76963-41-2 3033637
29
Ranitidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 66357-59-3, 66357-35-5 3001055
30
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
31
Clarithromycin Approved Phase 4 81103-11-9 84029
32
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
33
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
34
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128794-94-5 5281078
35
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
36
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
37
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 5271565 637568
38
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
39
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
40
Propranolol Approved, Investigational Phase 4 525-66-6 4946
41
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
42
Polidocanol Approved Phase 4,Phase 3,Phase 2,Phase 1 9002-92-0
43
Sodium Tetradecyl Sulfate Approved, Investigational Phase 4,Phase 2,Not Applicable 1191-50-0, 139-88-8 14492 5248
44
Trimebutine Approved Phase 4 39133-31-8
45
Verapamil Approved Phase 4 52-53-9 2520
46
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
47
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
48
Furazolidone Approved, Investigational, Vet_approved Phase 4,Not Applicable 67-45-8 3435 5323714
49
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Not Applicable
50
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585

Interventional clinical trials:

(show top 50) (show all 1281)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
2 Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants. Unknown status NCT02806453 Phase 4
3 Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
4 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Unknown status NCT01503476 Phase 4
5 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
6 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
7 Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
8 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate Unknown status NCT02278081 Phase 4 lansoprazole;placebo
9 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
10 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
11 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4 Deflux;Vantris
12 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
13 PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena Unknown status NCT00526006 Phase 4 esomeprazole
14 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4 Esomeprazole;Placebo
15 Clinical Study of Laparoscopic Non Banded Vertical Gastroplasty in Bariatric Surgery Unknown status NCT02050477 Phase 4
16 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
17 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection Unknown status NCT00156546 Phase 4 antibiotic to reduce the recurrence of infection
18 Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID Unknown status NCT00235053 Phase 4 fluticasone/salmeterol DISKUS 250/50
19 Study of Long-Term Use of Proton-Pump-Inhibitors in General Practice Unknown status NCT00363701 Phase 4 esomeprazole
20 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
21 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
22 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
23 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed NCT00660660 Phase 4 Esomeprazole;Placebo
24 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) Completed NCT00246909 Phase 4 Pantoprazole
25 Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic Rhinosinusitis Completed NCT03086070 Phase 4 Omeprazole 20mg;Placebo oral capsule
26 Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
27 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
28 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4 Lansoprazole
29 Do Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Predict Response to Treatment? Completed NCT00444145 Phase 4 Prevacid
30 Esomeprazole and Gastric Emptying of Beer Completed NCT00472550 Phase 4 esomeprazole 20 mg
31 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disea Completed NCT00628342 Phase 4 Esomeprazole;Esomeprazole;Placebo
32 On Demand Treatment of Reflux Disease Completed NCT00184522 Phase 4 Aflurax;esomeprazole
33 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Dise Completed NCT00629564 Phase 4 Esomeprazole;Esomeprazole
34 Sleep Disorders and Gastroesophageal Reflux Disease (GERD) Completed NCT00287391 Phase 4 Rabeprazole
35 A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD) Completed NCT00216489 Phase 4 rabeprazole sodium
36 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Completed NCT00926276 Phase 4
37 Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B Completed NCT03128736 Phase 4 Esomeprazole group;Dexlansoprazole group
38 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
39 Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy Completed NCT02470117 Phase 4 Alginate-based reflux suppressant;magnesium-aluminium antacid gel
40 Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD) Completed NCT00637845 Phase 4 Esomeprazole Magnesium;Lansoprazole
41 Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv Completed NCT00626262 Phase 4 Esomeprazole
42 Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506) Completed NCT00261339 Phase 4 Pantoprazole
43 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
44 A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn Completed NCT00237367 Phase 4 rabeprazole and pantoprazole
45 Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux Completed NCT00373997 Phase 4
46 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00242736 Phase 4 Esomeprazole
47 Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation Completed NCT03116841 Phase 4 Vonoprazan
48 The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity Completed NCT02689999 Phase 4 Dexrabeprazole 10 mg Enteric-Coated Tablets
49 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Completed NCT00574925 Phase 4 Esomeprazole
50 Validation of RDQ Questionnaire Completed NCT00291746 Phase 4 Esomeprazole

Search NIH Clinical Center for Gastroesophageal Reflux

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: gastroesophageal reflux

Genetic Tests for Gastroesophageal Reflux

Genetic tests related to Gastroesophageal Reflux:

# Genetic test Affiliating Genes
1 Gastroesophageal Reflux 29

Anatomical Context for Gastroesophageal Reflux

MalaCards organs/tissues related to Gastroesophageal Reflux:

41
Testes, Lung, Kidney, Bone, Liver, Tongue, Prostate

Publications for Gastroesophageal Reflux

Articles related to Gastroesophageal Reflux:

(show top 50) (show all 1536)
# Title Authors Year
1
Specific Features of Gastroesophageal Reflux Disease in Patients with Overweight (Basis for Personalized Treatment). ( 29923009 )
2018
2
Gastroesophageal reflux symptoms are not sufficient to guide esophageal function testing in lung transplant candidates. ( 29444329 )
2018
3
Gastroesophageal Reflux Frequency, Severity, Age of Onset, Family History and Acid Suppressive Therapy Predict Barrett Esophagus in a Large Population. ( 29356784 )
2018
4
Management of gastroesophageal reflux disease in adults: a pharmacist's perspective. ( 29892570 )
2018
5
Survey on the Adherence to the 2009 NASPGHAN-ESPGHAN Gastroesophageal Reflux Guidelines by Brazilian Paediatricians. ( 29394212 )
2018
6
Scintigraphic Evaluation of Esophageal Motility and Gastroesophageal Reflux in Patients Presenting with Upper Respiratory Tract Symptoms. ( 29430111 )
2018
7
What Is the Impact of High-Resolution Manometry in the Functional Diagnostic Workup of Gastroesophageal Reflux Disease? ( 29888238 )
2018
8
Analysis of Growth, Nutritional Status and Hospital Visitation Scores Associated with Reflux After Nissen Fundoplication in Neurologically Impaired Children with Gastroesophageal Reflux. ( 29018932 )
2018
9
Prevalence of Gastroesophageal Reflux Disease in Saudi Arabia. ( 29416581 )
2018
10
Diagnosis and Management of Gastroesophageal Reflux in Preterm Infants. ( 29915158 )
2018
11
Chronic Obstructive Pulmonary Disease Exacerbations Are Influenced by Gastroesophageal Reflux Disease. ( 29428028 )
2018
12
The Relationship between Primary Acquired Nasolacrimal Duct Obstruction and Gastroesophageal Reflux. ( 29897254 )
2018
13
Impact of Esophageal Atresia on the Success of Fundoplication for Gastroesophageal Reflux. ( 29628411 )
2018
14
Use of Esophageal pH Monitoring to Minimize Proton-Pump Inhibitor Utilization in Patients with Gastroesophageal Reflux Symptoms. ( 29959725 )
2018
15
Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma - where do we stand? ( 29972731 )
2018
16
Streptococcus agalactiae meningoencephalitis associated with gastroesophageal reflux disease and chronic proton pump inhibitors use, in a 9A month-old infant: a case report. ( 29390957 )
2018
17
Indications for total esophagogastric dissociation in children with gastroesophageal reflux disease. ( 29435660 )
2018
18
Pharyngeal manifestations of gastroesophageal reflux disease. ( 29392364 )
2018
19
Predictive Biomarkers of Gastroesophageal Reflux Disease and Barrett's Esophagus in World Trade Center Exposed Firefighters: a 15 Year Longitudinal Study. ( 29449669 )
2018
20
The effect of dietary carbohydrate on gastroesophageal reflux disease. ( 29339035 )
2018
21
Systematic review: methodological flaws in racial/ethnic reporting for gastroesophageal reflux disease. ( 29444213 )
2018
22
Clinicopathology and Survival in Patients with Gastroesophageal Reflux After Radical Surgery of Proximal Gastric Cancer. ( 29397493 )
2018
23
A systematic review with meta-analysis of the prevalence of gastroesophageal reflux in congenital diaphragmatic hernia pediatric survivors. ( 29444224 )
2018
24
Oral manifestations of gastroesophageal reflux disease in children: A preliminary observational study. ( 29970628 )
2018
25
Initial Experience of Endoscopic Radiofrequency Waves Delivery to the Lower Esophageal Sphincter (Stretta Procedure) on Symptomatic Gastroesophageal Reflux Disease Post-Sleeve Gastrectomy. ( 29905881 )
2018
26
Utility of Water Siphon Maneuver for Eliciting Gastroesophageal Reflux During Barium Esophagography: Correlation With Histologic Findings. ( 29894215 )
2018
27
Novel Surgical Treatments for Gastroesophageal Reflux Disease: Systematic Review of Magnetic Sphincter Augmentation and Electric Stimulation Therapy. ( 29915626 )
2018
28
Nasal high-frequency oscillatory ventilation inhibits gastroesophageal reflux in the neonatal period. ( 29438810 )
2018
29
Gastroesophageal Reflux: Regurgitation in the Infant Population. ( 29413212 )
2018
30
Fiber-enriched diet helps to control symptoms and improves esophageal motility in patients with non-erosive gastroesophageal reflux disease. ( 29881238 )
2018
31
Gastroesophageal reflux symptoms and nasal symptoms affect the severity of bronchitis symptoms in patients with chronic obstructive pulmonary disease. ( 29773294 )
2018
32
Phenotypes of Jackhammer esophagus in patients with typical symptoms of gastroesophageal reflux disease responsive to proton pump inhibitors. ( 29967357 )
2018
33
Guideline for Management of Pediatric Gastroesophageal Reflux. ( 29955834 )
2018
34
Association of esophageal dilatation in chest CT scan with gastroesophageal reflux disease: A case control study. ( 29962193 )
2018
35
Low back pain and gastroesophageal reflux in patients with COPD: the disease in the breath. ( 29403270 )
2018
36
Esophagography and gastroesophageal reflux disease: utilization and utility. ( 29427043 )
2018
37
Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders. ( 29913281 )
2018
38
Medical Therapy of Gastroesophageal Reflux Disease Beyond Proton Pump Inhibitors: Where Are We Heading? ( 29888239 )
2018
39
Surgical management of gastroesophageal reflux disease in patients with systemic sclerosis. ( 29435755 )
2018
40
Mucosal Impedance: a New Approach to Diagnosing Gastroesophageal Reflux Disease and Eosinophilic Esophagitis. ( 29886566 )
2018
41
Characterization of the nasopharyngeal and middle ear microbiota in gastroesophageal reflux-prone versus gastroesophageal reflux non-prone children. ( 29404836 )
2018
42
Focus on gastroesophageal reflux (GER) and laryngopharyngeal reflux (LPR): new pragmatic insights in clinical practice. ( 29436209 )
2018
43
Gastroesophageal Reflux in the Intensive Care Unit Patient. ( 29413207 )
2018
44
Esophageal Atresia with Tracheoesophageal Fistula and Gastroesophageal Reflux in Children: Dental Considerations and Case Report. ( 29750630 )
2018
45
Diagnostic Investigations of Gastroesophageal Reflux Disease: Who and When to Refer and for What Test? ( 29888237 )
2018
46
Acid Suppression for Gastroesophageal Reflux Disease in Infants. ( 29436357 )
2018
47
Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database. ( 29946474 )
2018
48
Tri-comparison of Laparoscopic Nissen, Hill, and Nissen-Hill Hybrid Repairs for Uncomplicated Gastroesophageal Reflux Disease. ( 27813017 )
2017
49
Prevalence and Correlates of Gastroesophageal Reflux Disease in Southern Iran: Pars Cohort Study. ( 28894514 )
2017
50
Emerging dilemmas in the diagnosis and management of gastroesophageal reflux disease. ( 29034088 )
2017

Variations for Gastroesophageal Reflux

ClinVar genetic disease variations for Gastroesophageal Reflux:

6
(show all 24)
# Gene Variation Type Significance SNP ID Assembly Location
1 ABCC8 NM_000352.4(ABCC8): c.3517G> A (p.Val1173Met) single nucleotide variant Likely pathogenic rs141322087 GRCh37 Chromosome 11, 17426099: 17426099
2 ABCC8 NM_000352.4(ABCC8): c.3517G> A (p.Val1173Met) single nucleotide variant Likely pathogenic rs141322087 GRCh38 Chromosome 11, 17404552: 17404552
3 FAM120AOS NM_198841.3(FAM120AOS): c.743C> T (p.Thr248Ile) single nucleotide variant Likely pathogenic rs140119177 GRCh38 Chromosome 9, 93447639: 93447639
4 FAM120AOS NM_198841.3(FAM120AOS): c.743C> T (p.Thr248Ile) single nucleotide variant Likely pathogenic rs140119177 GRCh37 Chromosome 9, 96209921: 96209921
5 46;XY;t(9;16)(p24;q22)dn Translocation Pathogenic
6 46;XY;t(3;5)(q23;q13)dn Translocation Likely pathogenic
7 46;XX;t(4;14)(p15.2;q13)dn Translocation Likely pathogenic
8 Translocation Pathogenic
9 ZNF469 NM_001127464.2(ZNF469): c.470G> A (p.Gly157Glu) single nucleotide variant Uncertain significance rs781096189 GRCh38 Chromosome 16, 88427940: 88427940
10 ZNF469 NM_001127464.2(ZNF469): c.470G> A (p.Gly157Glu) single nucleotide variant Uncertain significance rs781096189 GRCh37 Chromosome 16, 88494348: 88494348
11 RPS6KA3 NM_004586.2(RPS6KA3): c.533C> G (p.Ala178Gly) single nucleotide variant Likely pathogenic rs1057518914 GRCh37 Chromosome X, 20211665: 20211665
12 RPS6KA3 NM_004586.2(RPS6KA3): c.533C> G (p.Ala178Gly) single nucleotide variant Likely pathogenic rs1057518914 GRCh38 Chromosome X, 20193547: 20193547
13 COL5A1 NM_000093.4(COL5A1): c.608G> T (p.Gly203Val) single nucleotide variant Likely pathogenic GRCh37 Chromosome 9, 137593133: 137593133
14 COL5A1 NM_000093.4(COL5A1): c.608G> T (p.Gly203Val) single nucleotide variant Likely pathogenic GRCh38 Chromosome 9, 134701287: 134701287
15 CHAT NM_020549.4(CHAT): c.1061C> T (p.Thr354Met) single nucleotide variant Conflicting interpretations of pathogenicity rs769234940 GRCh37 Chromosome 10, 50835781: 50835781
16 CHAT NM_020549.4(CHAT): c.1061C> T (p.Thr354Met) single nucleotide variant Conflicting interpretations of pathogenicity rs769234940 GRCh38 Chromosome 10, 49627735: 49627735
17 CHAT NM_020549.4(CHAT): c.2081C> G (p.Ser694Cys) single nucleotide variant Pathogenic rs201439531 GRCh37 Chromosome 10, 50872926: 50872926
18 CHAT NM_020549.4(CHAT): c.2081C> G (p.Ser694Cys) single nucleotide variant Pathogenic rs201439531 GRCh38 Chromosome 10, 49664880: 49664880
19 ABCC8 NM_000352.4(ABCC8): c.1793G> A (p.Arg598Gln) single nucleotide variant Likely pathogenic GRCh38 Chromosome 11, 17430838: 17430838
20 ABCC8 NM_000352.4(ABCC8): c.1793G> A (p.Arg598Gln) single nucleotide variant Likely pathogenic GRCh37 Chromosome 11, 17452385: 17452385
21 ZNF469 NM_001127464.2(ZNF469): c.2569A> G (p.Asn857Asp) single nucleotide variant Uncertain significance GRCh37 Chromosome 16, 88496447: 88496447
22 ZNF469 NM_001127464.2(ZNF469): c.2569A> G (p.Asn857Asp) single nucleotide variant Uncertain significance GRCh38 Chromosome 16, 88430039: 88430039
23 ZNF469 NM_001127464.2(ZNF469): c.9448G> A (p.Gly3150Ser) single nucleotide variant Uncertain significance rs887755283 GRCh37 Chromosome 16, 88503410: 88503410
24 ZNF469 NM_001127464.2(ZNF469): c.9448G> A (p.Gly3150Ser) single nucleotide variant Uncertain significance rs887755283 GRCh38 Chromosome 16, 88437002: 88437002

Expression for Gastroesophageal Reflux

Search GEO for disease gene expression data for Gastroesophageal Reflux.

Pathways for Gastroesophageal Reflux

Pathways related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.18 CCK CXCL8 GCG GHRL HRH2 MLN
2
Show member pathways
12.13 IL1B PTGS1 PTGS2 TP53
3
Show member pathways
12.03 CXCL8 IL1B PTGS2 TP53
4 11.74 CXCL8 IL1B TP53
5 11.66 CXCL8 IL1B PTGS2
6 11.54 CXCL8 IL1B PTGS2 TP53
7
Show member pathways
11.45 CXCL8 IL1B PTGS2
8 11.31 CXCL8 IL1B PTGS2 TP53
9 11.29 CXCL8 PTGS2 TP53
10 11.23 CXCL8 IL1B PTGS2
11 10.7 PTGS1 PTGS2
12 10.3 CCK GAST
13 10.08 CXCL8 PTGS1 PTGS2
14 10.02 GAST HRH2

GO Terms for Gastroesophageal Reflux

Cellular components related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CCK CCL26 CXCL8 GAST GCG GHRL
2 organelle membrane GO:0031090 9.33 CYP2C19 PTGS1 PTGS2
3 extracellular region GO:0005576 9.32 CCK CCL26 CXCL8 GAST GCG GHRL

Biological processes related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.76 CXCL8 GHRL PTGS1 PTGS2
2 G-protein coupled receptor signaling pathway GO:0007186 9.65 CCK CCL26 CXCL8 GAST GCG GHRL
3 inflammatory response GO:0006954 9.63 CCL26 CXCL8 IL1B PTGS1 PTGS2 TRPV1
4 neutrophil chemotaxis GO:0030593 9.58 CCL26 CXCL8 IL1B
5 positive regulation of protein oligomerization GO:0032461 9.51 CCK TP53
6 prostaglandin biosynthetic process GO:0001516 9.49 PTGS1 PTGS2
7 cellular response to ATP GO:0071318 9.48 PTGS2 TRPV1
8 cyclooxygenase pathway GO:0019371 9.43 PTGS1 PTGS2
9 positive regulation of nitric oxide biosynthetic process GO:0045429 9.43 IL1B PTGS2 TRPV1
10 positive regulation of fever generation GO:0031622 9.37 IL1B PTGS2
11 fever generation GO:0001660 9.32 IL1B TRPV1
12 regulation of signaling receptor activity GO:0010469 9.32 CCK CCL26 CXCL8 GAST GCG GHRL

Molecular functions related to Gastroesophageal Reflux according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.33 CCK NTS PYY
2 hormone activity GO:0005179 9.1 CCK GAST GCG GHRL MLN PYY
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS1 PTGS2

Sources for Gastroesophageal Reflux

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet